|Security||HCM / Hutchison China MediTech Limited (44842L103)|
|Institutional Value||$ 1,011,115,000 USD|
HNCMF / Hutchison China Meditech Ltd.|
Institutional Stock Ownership and Shareholders
Hutchison China MediTech Limited (NASDAQ:HCM) has 39 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55,260,625 shares.
Largest shareholders include
CK Hutchison Holdings Ltd, Prudential Plc, Mitsui & Co Ltd, Oppenheimer Funds Inc, Karst Peak Capital Ltd, JP Morgan Chase & Co, Schroder Investment Management Group, Wellington Management Group LLP, Bellevue Group AG, and Allianz Asset Management AG.
Hutchison China MediTech Limited (NASDAQ:HCM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|WELLS FARGO & COMPANY/MN||27,087||27,639||2.04||801||834||4.12|
|Sumitomo Mitsui Trust Holdings, Inc.||108,085||121,430||12.35||3,195||3,660||14.55|
|Prince Street Capital Management LLC||81,400||81,400||0.00||2,406||2,453||1.95|
|HSBC HOLDINGS PLC||64,753||0||-100.00||2,553||0||-100.00|
|BANK OF AMERICA CORP /DE/||3,594||3,067||-14.66||106||92||-13.21|
|GSA CAPITAL PARTNERS LLP||201,268||222,345||10.47||5,949||6,701||12.64|
|PIONEER INVESTMENT MANAGEMENT INC||54,599||54,599||0.00||1,614||1,645||1.92|
|UBS Group AG||2,612||431||-83.50||78||13||-83.33|
|MANUFACTURERS LIFE INSURANCE COMPANY, THE||45,617||110,534||142.31||1,348||3,332||147.18|
|CASTLEARK MANAGEMENT LLC||4,500||0||-100.00||133||0||-100.00|
|MARSHALL WACE ASIA Ltd||10,620||320|
|State of New Jersey Common Pension Fund D||87,945||2,651|
|Allianz Asset Management AG||237,973||303,729||27.63||7,034||9,154||30.14|
|BAILLIE GIFFORD & CO||206,140||204,663||-0.72||6,093||6,169||1.25|
|MCKINLEY CAPITAL MANAGEMENT LLC /DELAWARE||24,238||23,222||-4.19||717||700||-2.37|
|Renaissance Technologies LLC||149,800||4,428|
|ROYAL BANK OF CANADA||6,747||203||-96.99||199||6||-96.98|
|Folger Hill Asset Management LP||42,772||43,840||2.50||1,264||1,321||4.51|
|Tower Research Capital LLC (TRC)||200||0||-100.00||6||0||-100.00|
|Hudson Bay Capital Management LP||17,200||17,200||0.00||508||518||1.97|
|Bellevue Group AG||302,420||332,536||9.96||8,940||10,023||12.11|
|Advisor Group, Inc.||352||293||-16.76||10||9||-10.00|
|GEODE CAPITAL MANAGEMENT, LLC||0||14,196||0||427|
|OPPENHEIMER FUNDS INC||1,684,770||2,972,947||76.46||49,802||89,604||79.92|
|DekaBank Deutsche Girozentrale||30,000||27,000||-10.00||866||826||-4.62|
|PERCEPTIVE ADVISORS LLC||10,000||10,000||0.00||296||301||1.69|
|CK Hutchison Holdings Ltd||36,666,667|
|Bt Investment Management Ltd||16,936||18,166||7.26||500,628||547,523||9.37|
|MITSUI & CO LTD||3,214,404|
|SCHRODER INVESTMENT MANAGEMENT GROUP||1,281,443||1,515,640||18.28||37,879||46,348||22.36|
|Karst Peak Capital Ltd||2,005,580||1,842,311||-8.14||59,285||55,527||-6.34|
|ALPS ADVISORS INC||191,933||5,785|
|Harvest Fund Management Co., Ltd||164,184||0||-100.00||4,852||0||-100.00|
|Wellington Management Group LLP||580,527||1,172,897||102.04||17,161||35,350||105.99|
|JP Morgan Chase & Co||1,527,742||1,585,723||3.80||45,159||47,794||5.83|
|AQR CAPITAL MANAGEMENT LLC||48,809||0||-100.00||1,443||0||-100.00|
|CITADEL ADVISORS LLC||9,674||7,029||-27.34||286||212||-25.87|
|INDUS CAPITAL PARTNERS, LLC||24,800||24,800||0.00||733||747||1.91|
|DEUTSCHE BANK AG\||64,233||800||-98.75||1,898||24||-98.74|
|Jabre Capital Partners S.A.||39,087||37,058||-5.19||1,155||1,117||-3.29|
|MILLENNIUM MANAGEMENT LLC||34,129||27,004||-20.88||1,009||814||-19.33|
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca (AZN.L) aims to move from simply supplying drugs to become a broad healthcare provider in China.
Discussion: Novocure (NVCR), a midcap biopharma with about $4bn in market capitlization, has seen a tripling of its valuation this year on the back of a slew of positive news. Just about a year ago, its product candidate OPTUNE, already approved in 2011 to treat glioblastoma, saw positive phase 3 results in a trial in newly diagnosed glioblastoma patients, a brain cancer that is notoriously difficult to treat. (0-1)
China’s nascent pharmaceuticals industry has just celebrated a landmark moment. A cancer drug called fruquintinib has become the first home-grown oncology medication ever to be approved by Chinese regulators. In fact, apart from Artemisinin, an anti-malarial, China has never discovered, developed and commercialised a drug of its own. This is a big deal for the country and a watershed moment in China’s path towards becoming a pharmaceuticals powerhouse.
LONDON (Reuters) - Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for “made in China” medicine.
(Aug 3): It’s been less than a year since Beijing cut back red tape on drug approvals and already Chinese patients can expect to get some breakthrough medicines before Americans. (7-1)
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (7-1)
Hutchison China MediTech Ltd (NASDAQ:HCM) Q2 2018 Earnings Conference Call July 27, 2018 9:00 AM ET
The following slide deck was published by Hutchison China MediTech Ltd. in conjunction with their 2018 Q1 earnings call.
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested. (627-7)
China is expanding efforts to keep its most promising companies from going public in Hong Kong or the US, with officials studying a new trading venue in Shanghai that would have lower thresholds for biotechnology and high-tech firms, people with knowledge of the matter said. (86-0)
as of ET